213 related articles for article (PubMed ID: 9934863)
21. Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies.
Mazzarino M; Biava M; de la Torre X; Fiacco I; Botrè F
Anal Bioanal Chem; 2013 Jun; 405(16):5467-87. PubMed ID: 23604525
[TBL] [Abstract][Full Text] [Related]
22. Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes.
Kim SY; Suzuki N; Santosh Laxmi YR; Rieger R; Shibutani S
Chem Res Toxicol; 2003 Sep; 16(9):1138-44. PubMed ID: 12971802
[TBL] [Abstract][Full Text] [Related]
23. Liquid chromatography-mass spectrometry method for the quantification of tamoxifen and its metabolite 4-hydroxytamoxifen in rat plasma: application to interaction study with biochanin A (an isoflavone).
Singh SP; Wahajuddin ; Ali MM; Kohli K; Jain GK
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Oct; 879(27):2845-51. PubMed ID: 21890435
[TBL] [Abstract][Full Text] [Related]
24. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
[TBL] [Abstract][Full Text] [Related]
25. Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate.
Driscoll JP; Kornecki K; Wolkowski JP; Chupak L; Kalgutkar AS; O'Donnell JP
Chem Res Toxicol; 2007 Oct; 20(10):1488-97. PubMed ID: 17892269
[TBL] [Abstract][Full Text] [Related]
26. Participation of P450 3A enzymes in rat hepatic microsomal retinoic acid 4-hydroxylation.
Martini R; Murray M
Arch Biochem Biophys; 1993 May; 303(1):57-66. PubMed ID: 8489266
[TBL] [Abstract][Full Text] [Related]
27. In vitro biotransformation of a novel antimalarial cysteine protease inhibitor in human liver microsomes.
Zhang Y; Guo X; Lin ET; Benet LZ
Pharmacology; 1999 Mar; 58(3):147-59. PubMed ID: 9925971
[TBL] [Abstract][Full Text] [Related]
28. Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins.
Dehal SS; Kupfer D
Cancer Res; 1996 Mar; 56(6):1283-90. PubMed ID: 8640815
[TBL] [Abstract][Full Text] [Related]
29. Oxidation of 1,2-epoxy-3-butene to 1,2:3,4-diepoxybutane by cDNA-expressed human cytochromes P450 2E1 and 3A4 and human, mouse and rat liver microsomes.
Seaton MJ; Follansbee MH; Bond JA
Carcinogenesis; 1995 Oct; 16(10):2287-93. PubMed ID: 7586124
[TBL] [Abstract][Full Text] [Related]
30. Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats.
Kim CS; Choi SJ; Park CY; Li C; Choi JS
Anticancer Res; 2010 Jan; 30(1):79-85. PubMed ID: 20150620
[TBL] [Abstract][Full Text] [Related]
31. Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline.
Murray M
Mol Pharmacol; 1992 Nov; 42(5):931-8. PubMed ID: 1435757
[TBL] [Abstract][Full Text] [Related]
32. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.
Boocock DJ; Brown K; Gibbs AH; Sanchez E; Turteltaub KW; White IN
Carcinogenesis; 2002 Nov; 23(11):1897-901. PubMed ID: 12419838
[TBL] [Abstract][Full Text] [Related]
33. Ethosuximide is primarily metabolized by CYP3A when incubated with isolated rat liver microsomes.
Sarver JG; Bachmann KA; Zhu D; Klis WA
Drug Metab Dispos; 1998 Jan; 26(1):78-82. PubMed ID: 9443857
[TBL] [Abstract][Full Text] [Related]
34. Tamoxifen metabolism in rat liver microsomes: identification of a dimeric metabolite derived from free radical intermediates by liquid chromatography/mass spectrometry.
Jones RM; Yuan ZX; Lim CK
Rapid Commun Mass Spectrom; 1999; 13(4):211-5. PubMed ID: 10097399
[TBL] [Abstract][Full Text] [Related]
35. No effect on pharmacokinetics of tamoxifen and 4-hydroxytamoxifen by multiple doses of red clover capsule in rats.
Raju KS; Taneja I; Valicherla GR; Challagundla MK; Rashid M; Syed AA; Gayen JR; Singh SP; Wahajuddin M
Sci Rep; 2015 Nov; 5():16126. PubMed ID: 26530625
[TBL] [Abstract][Full Text] [Related]
36. Metabolism of phencyclidine by human liver microsomes.
Laurenzana EM; Owens SM
Drug Metab Dispos; 1997 May; 25(5):557-63. PubMed ID: 9152594
[TBL] [Abstract][Full Text] [Related]
37. The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy.
Dehal SS; Brodie AM; Kupfer D
Drug Metab Dispos; 1999 Mar; 27(3):389-94. PubMed ID: 10064571
[TBL] [Abstract][Full Text] [Related]
38. Organ specificity of DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment.
Phillips DH; Hewer A; Osborne MR; Cole KJ; Churchill C; Arlt VM
Mutagenesis; 2005 Jul; 20(4):297-303. PubMed ID: 15928012
[TBL] [Abstract][Full Text] [Related]
39. alpha-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes.
Phillips DH; Carmichael PL; Hewer A; Cole KJ; Poon GK
Cancer Res; 1994 Nov; 54(21):5518-22. PubMed ID: 7923188
[TBL] [Abstract][Full Text] [Related]
40. The deuterium isotope effect for the alpha-hydroxylation of tamoxifen by rat liver microsomes accounts for the reduced genotoxicity of [D5-ethyl]tamoxifen.
Jarman M; Poon GK; Rowlands MG; Grimshaw RM; Horton MN; Potter GA; McCague R
Carcinogenesis; 1995 Apr; 16(4):683-8. PubMed ID: 7728943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
